Ruibing Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ruibing Chen has a total of 229 co-authors. Here are the top co-authors by number of shared publications:
- Lei Zhang
School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
5 shared publications - Yongjin J. Zhou
Division of Biotechnology, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, The People’s Republic of China
5 shared publications Xianghui Chen
Department of Pharmaceutical Botany, School of Pharmacy, Naval Medical University, Shanghai, China
4 shared publicationsJunze Ren
Department of Pharmaceutical Botany, School of Pharmacy, Naval Medical University, Shanghai 200433, China
3 shared publications- Yu Chen
State key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
3 shared publications - Zhaoyu Liu
Institute of Herbgenomics, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
3 shared publications
Latest Publications
- Open Access
- 13 November 2025
- Published by Springer Nature in Plant Molecular Biology
- Vol. 115 (6) , 127
Correction: Sbmyb111 act as a transcriptional activator of flavonoid synthesis in Scutellaria baicalensis
- 13 November 2025
- Published by Springer Nature in Plant Molecular Biology
- Vol. 115 (6) , 127
Open AccessCorrection: Sbmyb111 act as a transcriptional activator of flavonoid synthesis in Scutellaria baicalensis
- Open Access
- 6 October 2025
- Published by Elsevier in Industrial Crops and Products
- Vol. 236
Structural and functional assay of Scutellaria baicalensis gene SbMYB13, a potential flavonoid biosynthesis related transcription factor with four alternative isoforms
- 6 October 2025
- Published by Elsevier in Industrial Crops and Products
- Vol. 236
Open AccessStructural and functional assay of Scutellaria baicalensis gene SbMYB13, a potential flavonoid biosynthesis related transcription factor with four alternative isoforms
- 10 July 2025
- Published by Springer Nature in Plant Molecular Biology
- Vol. 115 (4) , 1-21
Sbmyb111 act as a transcriptional activator of flavonoid synthesis in Scutellaria baicalensis
Scutellaria baicalensis, a traditional medicinal plant originating in China, is widely cultivated for its therapeutic properties. The main bioactive substances in S. baicalensis are flavonoids, which exhibit extensive antibacterial and antiviral activities. However, the contents of these valuable natural product ingredients are relatively low in the plant. MYB transcription factors play crucial roles in regulating plant secondary metabolism, including flavonoid biosynthesis. While the regulation of MYB transcription factors has been extensively studied in various species, research on their role in S. baicalensis remains relatively scarce. In this study, we identified SbMYB111, belonging to the S7 subgroup of R2R3-MYB transcription factors, which functions as a transcriptional activator and is localized in the nucleus. Through heterologous overexpression of SbMYB111 in Arabidopsis thaliana and suppression expression in S. baicalensis, we demonstrated that SbMYB111 acts as a positive regulator in the biosynthesis of flavonoids. Furthermore, the yeast one-hybrid and dual-luciferase reporter gene assays validated that SbMYB111 activates the expression of SbC4H2, a key enzyme gene in the flavonoid biosynthesis pathway. This study provides a theoretical basis for understanding the transcriptional regulation mechanism of flavonoid synthesis and further developing medicinal resources of S.baicalensis.
- 10 July 2025
- Published by Springer Nature in Plant Molecular Biology
- Vol. 115 (4) , 1-21
Sbmyb111 act as a transcriptional activator of flavonoid synthesis in Scutellaria baicalensis
Scutellaria baicalensis, a traditional medicinal plant originating in China, is widely cultivated for its therapeutic properties. The main bioactive substances in S. baicalensis are flavonoids, which exhibit extensive antibacterial and antiviral activities. However, the contents of these valuable natural product ingredients are relatively low in the plant. MYB transcription factors play crucial roles in regulating plant secondary metabolism, including flavonoid biosynthesis. While the regulation of MYB transcription factors has been extensively studied in various species, research on their role in S. baicalensis remains relatively scarce. In this study, we identified SbMYB111, belonging to the S7 subgroup of R2R3-MYB transcription factors, which functions as a transcriptional activator and is localized in the nucleus. Through heterologous overexpression of SbMYB111 in Arabidopsis thaliana and suppression expression in S. baicalensis, we demonstrated that SbMYB111 acts as a positive regulator in the biosynthesis of flavonoids. Furthermore, the yeast one-hybrid and dual-luciferase reporter gene assays validated that SbMYB111 activates the expression of SbC4H2, a key enzyme gene in the flavonoid biosynthesis pathway. This study provides a theoretical basis for understanding the transcriptional regulation mechanism of flavonoid synthesis and further developing medicinal resources of S.baicalensis.
- Open Access
- 2 July 2025
- Published by Springer Nature in Microbial Cell Factories
- Vol. 24 (1) , 1-13
De novo biosynthesis of taxifolin in yeast peroxisomes
Yeast peroxisomes have been engineered as ideal synthetic compartments to enhance the heterologous biosynthesis of natural products, particularly terpenoids and fatty acid derivatives. This advantage is primarily attributed to the rich acetyl-CoA pool generated from the spatially specific fatty acid β-oxidation within peroxisomes. However, their potential for flavonoid biosynthesis has been largely underexplored, primarily due to limited knowledge regarding precursor transport, cofactor availability, and the redox environment in peroxisomes. In this study, we successfully compartmentalized the biosynthesis of taxifolin, a dihydroflavonol, in Saccharomyces cerevisiae peroxisomes. The result indicated that flavonoid biosynthesis in peroxisome offers a more efficient approach compared to its synthesis in the cytosol. This study managed to expand the application scope of peroxisome compartmentalization to flavonoid biosynthesis. By reinforcing the rate-limiting steps, optimizing cofactor supply and activation of fatty acids, we accomplished the de novo synthesis of taxifolin in peroxisomes for the first time, attaining a titer of 120.3 ± 2.4 mg/L in shake-flask fermentation using a minimal medium. These findings highlight the feasibility of peroxisomal compartmentalization for flavonoid biosynthesis, providing new insights and a framework for the biosynthesis of other high-value flavonoids using yeast peroxisomes.
- 2 July 2025
- Published by Springer Nature in Microbial Cell Factories
- Vol. 24 (1) , 1-13
Open AccessDe novo biosynthesis of taxifolin in yeast peroxisomes
Yeast peroxisomes have been engineered as ideal synthetic compartments to enhance the heterologous biosynthesis of natural products, particularly terpenoids and fatty acid derivatives. This advantage is primarily attributed to the rich acetyl-CoA pool generated from the spatially specific fatty acid β-oxidation within peroxisomes. However, their potential for flavonoid biosynthesis has been largely underexplored, primarily due to limited knowledge regarding precursor transport, cofactor availability, and the redox environment in peroxisomes. In this study, we successfully compartmentalized the biosynthesis of taxifolin, a dihydroflavonol, in Saccharomyces cerevisiae peroxisomes. The result indicated that flavonoid biosynthesis in peroxisome offers a more efficient approach compared to its synthesis in the cytosol. This study managed to expand the application scope of peroxisome compartmentalization to flavonoid biosynthesis. By reinforcing the rate-limiting steps, optimizing cofactor supply and activation of fatty acids, we accomplished the de novo synthesis of taxifolin in peroxisomes for the first time, attaining a titer of 120.3 ± 2.4 mg/L in shake-flask fermentation using a minimal medium. These findings highlight the feasibility of peroxisomal compartmentalization for flavonoid biosynthesis, providing new insights and a framework for the biosynthesis of other high-value flavonoids using yeast peroxisomes.
- 17 March 2025
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (10) , 1487-1496
De novo biosynthesis of plant lignans by synthetic yeast consortia
Reconstructing the biosynthesis of complex natural products such as lignans in yeast is challenging and can result in metabolic promiscuity, affecting the biosynthetic efficiency. Here we divide the lignan biosynthetic pathway across a synthetic yeast consortium with obligated mutualism and use ferulic acid as a metabolic bridge. This cooperative system successfully overcomes the metabolic promiscuity and synthesizes the common precursor, coniferyl alcohol. Furthermore, combined with systematic engineering strategies, we achieve the de novo synthesis of key lignan skeletons, pinoresinol and lariciresinol, and verify the scalability of the consortium by synthesizing complex lignans, including antiviral lariciresinol diglucoside. These results provide a starting engineering platform for the heterologous synthesis of lignans. In particular, the study illustrates that the yeast consortium with obligate mutualism is a promising strategy that mimics the metabolic division of labor among multiple plant cells, thereby improving the biosynthesis of long pathways and complex natural products.
- 17 March 2025
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (10) , 1487-1496
De novo biosynthesis of plant lignans by synthetic yeast consortia
Reconstructing the biosynthesis of complex natural products such as lignans in yeast is challenging and can result in metabolic promiscuity, affecting the biosynthetic efficiency. Here we divide the lignan biosynthetic pathway across a synthetic yeast consortium with obligated mutualism and use ferulic acid as a metabolic bridge. This cooperative system successfully overcomes the metabolic promiscuity and synthesizes the common precursor, coniferyl alcohol. Furthermore, combined with systematic engineering strategies, we achieve the de novo synthesis of key lignan skeletons, pinoresinol and lariciresinol, and verify the scalability of the consortium by synthesizing complex lignans, including antiviral lariciresinol diglucoside. These results provide a starting engineering platform for the heterologous synthesis of lignans. In particular, the study illustrates that the yeast consortium with obligate mutualism is a promising strategy that mimics the metabolic division of labor among multiple plant cells, thereby improving the biosynthesis of long pathways and complex natural products.
- Top Cited PapersOpen Access
- 4 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-10
De novo biosynthesis of the hops bioactive flavonoid xanthohumol in yeast
The flavonoid xanthohumol is an important flavor substance in the brewing industry that has a wide variety of bioactivities. However, its unstable structure results in its low content in beer. Microbial biosynthesis is considered a sustainable and economically viable alternative. Here, we harness the yeast Saccharomyces cerevisiae for the de novo biosynthesis of xanthohumol from glucose by balancing the three parallel biosynthetic pathways, prenyltransferase engineering, enhancing precursor supply, constructing enzyme fusion, and peroxisomal engineering. These strategies improve the production of the key xanthohumol precursor demethylxanthohumol (DMX) by 83-fold and achieve the de novo biosynthesis of xanthohumol in yeast. We also reveal that prenylation is the key limiting step in DMX biosynthesis and develop tailored metabolic regulation strategies to enhance the DMAPP availability and prenylation efficiency. Our work provides feasible approaches for systematically engineering yeast cell factories for the de novo biosynthesis of complex natural products.
- 4 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-10
Top Cited PapersOpen AccessDe novo biosynthesis of the hops bioactive flavonoid xanthohumol in yeast
The flavonoid xanthohumol is an important flavor substance in the brewing industry that has a wide variety of bioactivities. However, its unstable structure results in its low content in beer. Microbial biosynthesis is considered a sustainable and economically viable alternative. Here, we harness the yeast Saccharomyces cerevisiae for the de novo biosynthesis of xanthohumol from glucose by balancing the three parallel biosynthetic pathways, prenyltransferase engineering, enhancing precursor supply, constructing enzyme fusion, and peroxisomal engineering. These strategies improve the production of the key xanthohumol precursor demethylxanthohumol (DMX) by 83-fold and achieve the de novo biosynthesis of xanthohumol in yeast. We also reveal that prenylation is the key limiting step in DMX biosynthesis and develop tailored metabolic regulation strategies to enhance the DMAPP availability and prenylation efficiency. Our work provides feasible approaches for systematically engineering yeast cell factories for the de novo biosynthesis of complex natural products.
- 9 October 2023
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 41 (1) , 6-24
Simple phenylpropanoids: recent advances in biological activities, biosynthetic pathways, and microbial production
Microbial cell factories represent an alternative idea for efficient production of simple phenylpropanoids.
- 9 October 2023
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 41 (1) , 6-24
Simple phenylpropanoids: recent advances in biological activities, biosynthetic pathways, and microbial production
Microbial cell factories represent an alternative idea for efficient production of simple phenylpropanoids.
- Open Access
- 2 June 2023
- Published by Springer Nature in Research Square
De novo biosynthesis of the hops bioactive flavonoid xanthohumol in yeast
The flavonoid xanthohumol is an important flavor substance in the brewing industry that has a wide variety of bioactivities. However, its unstable structure is easily oxidized during the brewing process, resulting in its low content in beer. Moreover, its extraction and purification from plants requires laborious and expensive procedures. Microbial biosynthesis is considered a sustainable and economically viable alternative to supply natural products. However, the complex structures of natural products and regulation of the biosynthetic pathways make it challenging to construct and optimize the xanthohumol pathway in microbes. Here, we harnessed the brewing yeast Saccharomyces cerevisiae for the de novo biosynthesis of xanthohumol from glucose by modular fine-tuning of the competitive metabolic pathways, prenyltransferase engineering, enhancing precursor supply, substrate channeling, and peroxisomal engineering. These strategies significantly improved the production of the key xanthohumol precursor demethylxanthohumol (DMX) by 83-fold and achieved the de novo biosynthesis of xanthohumol for the first time in a microbial cell factory. We also revealed that prenylation is the key limiting step in DMX biosynthesis and that enhancing the supply of dimethylallyl pyrophosphate (DMAPP) and substrate channeling helps to drive the metabolic flux toward DMX biosynthesis, which should be helpful for improving the production of prenylated natural products. Our work provides feasible approaches for systematically engineering yeast cell factories for the de novo biosynthesis of complex natural products.
- 2 June 2023
- Published by Springer Nature in Research Square
Open AccessDe novo biosynthesis of the hops bioactive flavonoid xanthohumol in yeast
The flavonoid xanthohumol is an important flavor substance in the brewing industry that has a wide variety of bioactivities. However, its unstable structure is easily oxidized during the brewing process, resulting in its low content in beer. Moreover, its extraction and purification from plants requires laborious and expensive procedures. Microbial biosynthesis is considered a sustainable and economically viable alternative to supply natural products. However, the complex structures of natural products and regulation of the biosynthetic pathways make it challenging to construct and optimize the xanthohumol pathway in microbes. Here, we harnessed the brewing yeast Saccharomyces cerevisiae for the de novo biosynthesis of xanthohumol from glucose by modular fine-tuning of the competitive metabolic pathways, prenyltransferase engineering, enhancing precursor supply, substrate channeling, and peroxisomal engineering. These strategies significantly improved the production of the key xanthohumol precursor demethylxanthohumol (DMX) by 83-fold and achieved the de novo biosynthesis of xanthohumol for the first time in a microbial cell factory. We also revealed that prenylation is the key limiting step in DMX biosynthesis and that enhancing the supply of dimethylallyl pyrophosphate (DMAPP) and substrate channeling helps to drive the metabolic flux toward DMX biosynthesis, which should be helpful for improving the production of prenylated natural products. Our work provides feasible approaches for systematically engineering yeast cell factories for the de novo biosynthesis of complex natural products.
- Open Access
- 1 January 2023
- Published by Maximum Academic Press in Medicinal Plant Biology
- Vol. 2 (1)
A critical review of Andrographis paniculata
Andrographis paniculata, a traditional medicinal plant, is widely used to treat various disorders. According to traditional Chinese medicine (TCM) theory, it is intensely bitter in taste and cold-natured. Andrographolide and its derivates are the major bioactive compounds that show anti-inflammatory, anti-tumor, anti-diabetes, cardiovascular protection, neuroprotective, and hepatoprotective effects. In this review, we will focus on the application of TCM prescriptions and the modern bioactivities of Andrographis Herba. Due to the low content of andrographolide and derived lactones in the original species and the complexity of chemical structure, there is an urgent need to develop biotechnological methods for obtaining andrographolide and its derivatives sustainably. Nevertheless, the andrographolide biosynthetic pathway still needs to be fully elucidated in A. paniculata. Therefore, we further review recent progress in revealing the andrographolide biosynthetic pathway, combined with heterologous synthesis strategies of other plant diterpenoids to help create a cell factory with higher production of andrographolide in the future.
- 1 January 2023
- Published by Maximum Academic Press in Medicinal Plant Biology
- Vol. 2 (1)
Open AccessA critical review of Andrographis paniculata
Andrographis paniculata, a traditional medicinal plant, is widely used to treat various disorders. According to traditional Chinese medicine (TCM) theory, it is intensely bitter in taste and cold-natured. Andrographolide and its derivates are the major bioactive compounds that show anti-inflammatory, anti-tumor, anti-diabetes, cardiovascular protection, neuroprotective, and hepatoprotective effects. In this review, we will focus on the application of TCM prescriptions and the modern bioactivities of Andrographis Herba. Due to the low content of andrographolide and derived lactones in the original species and the complexity of chemical structure, there is an urgent need to develop biotechnological methods for obtaining andrographolide and its derivatives sustainably. Nevertheless, the andrographolide biosynthetic pathway still needs to be fully elucidated in A. paniculata. Therefore, we further review recent progress in revealing the andrographolide biosynthetic pathway, combined with heterologous synthesis strategies of other plant diterpenoids to help create a cell factory with higher production of andrographolide in the future.